Empowered Patient Podcast

Dr. Nerissa Kreher, Chief Medical Officer, Tiburio discusses the company's lead asset, TBR-760 as a novel treatment option for patients with non-functioning pituitary adenomas (NFPA), which are rare neuroendocrine tumors located in the pituitary gland.  She also speaks about the challenges facing patients even after surgical or radiation treatments for these pituitary tumors. @TiburioT #neuroendocrine  #pituitaryadenoma  #chiefmedicalofficer  #raredisease  #NFPA  Tiburio Therapeutics Download the PDF file of the interview here.

Venkat Nelabhotla, Chief Executive Officer, Vyome Therapeutics discusses the growing problem of antimicrobial resistance in medicine and how Vyome is working to tackle resistant dermatological conditions using their understanding of the skin microbiome.  Focusing first on acne, Vyome is developing VB-1953, a topical gel capable of killing resistant strains of P. acnes to help deliver solutions to the more than 10 million patients in the US, and more world-wide, with antibiotic resistant acne. @vyometx Vyome Therapeutics

Dr. Greg van Wyk, CMO and recently appointed CEO, Noxopharm talks about the Company's current milestones and upcoming news related to its lead clinical drug candidate, Veyonda, a chemotherapy and radiation enhancer that is being studied in men with late stage metastatic prostate cancer and that may have broad applicability in other cancer types.  Greg notes the explosion of mergers and acquisitions particularly in the oncology space due to increasing interest in combining one or more molecules in treatments. @Noxopharm #prostatecancer  #cancer  #chemotherapy  #radiation Noxopharm

Terri Wingham, Founder, A Fresh Chapter was diagnosed with an aggressive form of cancer when she was in her 30's.  As a result she founded A Fresh Chapter, giving cancer survivors and caregivers an opportunity to travel to foreign and US destinations to get outside of their comfort zone and discover new possibilities, community and purpose.  These odysseys are supplemented by online resources and financial underwriting from corporate sponsors including Eli Lilly. @afreshchapter #cancer A Fresh Chapter

Preston Klassen, MD Chief Medical Officer, Arena Pharmaceuticals talks about the challenges of treating Inflammatory Bowel Diseases (IBD) and Arena's developmental therapies for ulcerative colitis and Crohn's disease.  We also talk about the development of a treatment for related gastrointestinal pain with a non-opioid alternative. #Arena  #Ulcerativecolitis #GI  #IBD  #crohns @ArenaPharm  Arena Pharmaceuticals     Arena Pharmaceuticals

Dr. Jean-Marc Steens, Chief Medical Officer, Abivax reports on clinical results that continue to show advances in the chronic treatment and maintenance of moderate to severe ulcerative colitis using a new small molecule ABX464 in an oral treatment and potential applications for other inflammatory and neurological diseases.  Jean-Marc also explains how another molecule ABX196 is being tested to determine if it might increase the outcome of treatments for hepatocellular carcinoma, the most common liver cancer, in conjunction with Opdivo a checkpoint inhibitor that is being developed with Scripps Research, University of Chicago and BYU.  #ulcerativecolitis Abivax    

Bob Anderson PhD, Chief Scientific Officer, ImmusanT is an internationally recognized leader in celiac disease research.  He talks about the underlying causes of celiac, who is most likely to have an acquired immune response to fragments of the gluten protein, educating doctors about the need to test for celiac, the Phase 2 clinical trial results for Nexvax2 a therapeutic vaccine to treat celiac, and how the ImmusanT platform technology is allowing development of therapeutic vaccines for diabetes and other autoimmune conditions. @ImmusanT #celiac  #celiacdisease #diabetes  #autoimmunediseases #tcell  #glutenpeptides  #peptides  #gluten  #immunology ImmusanT 

Amit Etkin MD PhD is a professor of psychiatry and behavioral sciences at the Stanford School of Medicine and expert in the neural basis of emotional disorders.  He talks about a recent study published in Science Translational Medicine, of which he was the lead author physician, on his research that lead to the discovery of the first imaging biomaker for PTSD.  Using fMRI and TMS with EEG, Amit was able to identify which patients were most likely to be helped by different treatment plans for post-traumatic stress disorder.  This research was funded in part by Cohen Veterans Bioscience, a translational research organization dedicated to fast-tracking personalized diagnostics and therapeutics for brain health. Cohen Veterans Bioscience

Dr. Vimal Mehta, CEO and Founder, BioXcel Therapeutics talks about using artificial intelligence approaches in the development of drugs.  BioXcel's two most advanced clinical development programs are (1) BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders like schizophrenia, bipolar disorder, Alzheimer's and opioid addiction and (2) BXCL701, an immuno-oncology agent designed for the treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. BioXCel Therapeutics  

Marina Baroff, Senior Director, Service Innovation at Steps Through OC shines a light on the need to provide physical as well as emotional support to women living with ovarian cancer and their caregivers.  Marina talks about this new program of The Clearity Foundation with seed funding provided by the Susan Poorman Blackie Ovarian Cancer Foundation that matches patients and their caregivers with a professional ovarian cancer counselor at no charge.  This is not a support group but rather online, personalized treatment plans based on science and tailored to each person's unique situation. @stepsthrough @clearityfnd StepsThrough.org ClearityFoundation.org